Clinical Trial: Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate in Patient With Rare Tumor (Phase I Study)
Brief Summary: The purpose of this study is to determine the maximum tolerated dose of imatinib mesylate, given in association with a fixed dose of cyclophosphamide (50 mg bid).
Detailed Summary:
Sponsor: Centre Oscar Lambret
Current Primary Outcome: For safety: NCI-CTCAE scale version 3.0 [ Time Frame: 42 days ]
Original Primary Outcome: Same as current
Current Secondary Outcome: For anti tumoral efficiency : RECIST criteria [ Time Frame: 70 days ]
Original Secondary Outcome: Same as current
Information By: Centre Oscar Lambret
Dates:
Date Received: January 11, 2010
Date Started: January 2009
Date Completion:
Last Updated: June 6, 2012
Last Verified: June 2012